Before starting
Required
- Baseline
- Full blood count
- Liver function tests If history suggests abnormal
- Serum creatinine (for creatinine clearance) or Estimated glomerular filtration rate If history suggests abnormal
Ongoing once stable
Consider if treatment longer than 6 months
- Every 3 months
- Full blood count
- Liver function tests
- Serum creatinine (for creatinine clearance) or Estimated glomerular filtration rate
Abnormal results
Respond to patient symptoms and conditions
Consider stopping treatment and contacting a specialist if any of the following develop:
- hepatotoxicity
- unusual pigmentation
- systemic lupus erythematosus (SLE) or lupus-like or serum sickness-like syndromes
- hypersensitivity syndrome consisting of cutaneous reaction (such as rash or exfoliative dermatitis)
- eosinophilia
- hepatitis
- pneumonitis
- nephritis
- myocarditis
- pericarditis
- fever
- lymphadenopathy
Bibliography
- Buckinghamshire Formulary. Buckinghamshire Healthcare NHS Trust and Buckinghamshire CCG. Minocycline for use in dermatology – Amber Initiation Guideline. Uploaded May 2020 [cited 30/07/2020]
- Ledingham J, Gullick N, Irving K et al. BSR and BHPR Standards, Guidelines and Audit Working Group, BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs, Rheumatology, Volume 56, Issue 6, June 2017, Pages 865–868 [cited 09/01/2020]
- Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press [cited 09/01/2020]
- Mylan Pharma Ltd. Summary of Product Characteristics – Minocycline 100mg film coated tablets. Last revised 11/2020 [cited 09/01/2020]
- NICE Clinical Knowledge Summaries (CKS). Acne Vulgaris: Scenario: management of acne vulgaris in primary care. Updated Dec 2019 [cited 21/02/2020]